SCHEMBL7894074

SCHEMBL7894074

Cc1ccc(C(=O)Nc2sc(C)cc2C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.57
NPC1 O15118 6/20 0.57
RAB9A P51151 5/20 0.57
NPSR1 Q6W5P4 3/20 0.57
PTPN5 P54829 1/20 0.57
KDM4E B2RXH2 2/20 0.56
POLB P06746 1/20 0.56
ALDH1A1 P00352 6/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
HTT P42858 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
ERO1A Q96HE7 1/20 0.54
GRIN2C Q14957 1/20 0.53
HPGD P15428 3/20 0.50
KCNK2 O95069 1/20 0.48
LMNA P02545 2/20 0.48
GAA P10253 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
P2RY14 Q15391 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7894867 0.89 MAPT (0.71) MAPTNPC1RAB9ANPSR1PTPN5
SCHEMBL7904120 0.87 NPC1 (0.68) MAPTNPC1RAB9ANPSR1PTPN5
SCHEMBL7904197 0.87 GRIN2C (0.70) MAPTNPC1RAB9ANPSR1PTPN5
SCHEMBL7894076 0.86 ALDH1A1 (0.58) MAPTNPC1RAB9ANPSR1PTPN5
SCHEMBL28257103 0.85 MAPT (0.54) MAPTNPC1RAB9ANPSR1PTPN5
SCHEMBL5788877 0.81 MAPT (0.60) MAPTNPC1RAB9ANPSR1KDM4E
SCHEMBL21411372 0.77 ALDH1A1 (0.49) MAPTNPC1RAB9ANPSR1PTPN5
SCHEMBL11466890 0.76 HPGD (0.50) MAPTNPC1RAB9ANPSR1PTPN5
SCHEMBL3083629 0.76 IKBKB (0.50) MAPTNPC1RAB9ANPSR1PTPN5
SCHEMBL6310194 0.76 LMNA (0.50) MAPTNPC1RAB9ANPSR1PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 US disclosed
CN-108938625-B Application of 2-arylformamido thiophene-3-carboxylic acid derivative as ANO1 protein inhibitor and preparation method thereof 北京大学 2021-06-29 CN disclosed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
US-10273214-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2019-04-30 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed
US-8822462-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2014-09-02 US disclosed
US-8822462-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2014-09-02 US disclosed
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2012-02-02 US disclosed
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2012-02-02 US disclosed
WO-2010088414-A2 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS EMORY UNIVERSITY (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10273214-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions GRIN1, GRIN2A, GRIN2B MAPT 768/4885NPC1 970/4885RAB9A 727/4885
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions GRIN1, GRIN2A, GRIN2B MAPT 768/4885NPC1 970/4885RAB9A 727/4885
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS GRIN1, GRIN2A, GRIN2B MAPT 768/4885NPC1 970/4885RAB9A 727/4885
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH MAPT 2844/4885NPC1 320/4885RAB9A 1953/4885
US-11840527-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH MAPT 2844/4885NPC1 320/4885RAB9A 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.